

## Cytotoxic Evaluation of (*E*)-1-(2',4'-difluorobiphenyl-4-yl)-3-arylprop-2-en-1-one Derivatives

M. Fathimunnisa<sup>1</sup> and H. Manikandan<sup>2</sup>

<sup>1</sup>Department of Chemistry,  
AVC College (autonomous), Mannampandal - 609 305, Tamilnadu, INDIA.

<sup>2</sup>Department of Chemistry,  
Annamalai University, Annamalainagar - 608 002, Tamilnadu, INDIA.

(Received on: November 8, Accepted: November 17, 2017)

### ABSTRACT

A series of (*E*)-1-(2',4'-difluorobiphenyl-4-yl)-3-arylprop-2-en-1-one derivatives were synthesized and *in vitro* cytotoxic activity of the compounds were evaluated against Hep-2 cell line by MTT assay. The structure activity relationship based on the type of substituent on C-3 propenones was explored.

**Keywords:** Cytotoxic activity; MTT assay; Hep-2 cell line; Difluorobiphenyl chalcone.

### INTRODUCTION

Although there is a rapid development in diagnosing and treating cancer, it remains a major threat to the patients. It is a challenge for the chemists to develop new anticancer drugs with high selectivity and absorptivity than the existing drugs. To overcome the side effects emerging from the presently available drugs, there is a need to develop better cytotoxic agents to prevent such a problem<sup>1</sup>.

Chalcones possess wide range of therapeutic and pharmacological activities due to the presence of methylene and carbonyl moieties in their structure. They present in many naturally occurring vascular plants not only in their terrestrial parts but also in roots, flakes and seeds. A large variety chalcone based derivatives were reported and identified as better anticancer agent. These compounds exhibits a wide variety of pharmacological activities which includes anticancer, antiinflammatory, immunomodulatory, antibacterial, and immunosuppressive, as well as antiprotozoan activity, including trypanocidal, leishmanicidal, and antimalarial<sup>2-8</sup>. The biphenyl moiety is also found in many natural products that exhibits a wide variety of biological activities such as anti-cancer<sup>9-12</sup>, anti-angiogenic<sup>9,11</sup>, anti-viral<sup>13</sup> and have the ability to display enhanced fluorescence<sup>14</sup>. We recently reported the synthesis, characterization, *in vitro* antimicrobial activity against various microbes and *in silico* docking studies against cancer protein 4LRH<sup>15</sup>. From the molecular docking studies it was concluded that the

synthesized difluorobiphenyl chalcones was found to exhibit anticancer activity against the tested ligand. With the aim to evaluate the *in vitro* cytotoxic activity of the synthesized analogues, in the present study the cytotoxic activity was tested against Hep-2 cell line.

## EXPERIMENTAL


The cytotoxicity of the synthesized compounds were tested against Hep-2 cell lines using the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay<sup>16</sup>. The cells were seeded into a 96-well plate at a density of  $1.5 \times 10^4$  cells/well and incubated at 37 °C, 5 % CO<sub>2</sub>, for 24 h to allow the cells to attach. Cells were incubated with 10 μM of synthesized compounds into designated wells. After 48 h of incubation at 37 °C, 20 μL of MTT solution (4 mg/mL) was added to each well. The plates were further incubated for 4 h at 37 °C, allowing viable cells to change the yellow-colored MTT into dark-blue formazan crystals. Consequently, without disturbing the cells the MTT medium was removed from each well, and 100 μL of DMSO was added into each well. Plates were placed on a shaking table to thoroughly mix the formazan into the solvent. Finally, the absorbance was determined at 570 nm by microplate reader (Tecan infinite M200 pro multimode reader, Austria). The MTT assays were performed four times independently, and each independent experiment was done in triplicate. The percentage of survival was calculated using the formula:

$$\% \text{ Survival} = [\text{live cell number (test)/live cell number (control)}] \times 100$$

$$\text{Cytotoxicity (\%)} = 100 - \% \text{ survival}$$

## RESULTS AND DISCUSSION

Various (*E*)-1-(2',4'-difluorobiphenyl-4-yl)-3-arylprop-2-en-1-ones (**3a-l**) were prepared with excellent yield by Claisen-Schmidt condensation of 1-(2',4'-difluorobiphenyl-4-yl)ethanone (**1**) with various substituted aldehydes (**2a-l**) under basic condition as displayed in **Table 1** (**Scheme 1**).



Scheme 1


Table 1 Synthesis of (*E*)-1-(2',4'-difluorobiphenyl-4-yl)-3-arylprop-2-en-1-ones

Compound	Ar	Compound	Ar
<b>3a</b>	C <sub>6</sub> H <sub>5</sub>	<b>3g</b>	4-BrC <sub>6</sub> H <sub>4</sub>
<b>3b</b>	4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	<b>3h</b>	3-NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub>
<b>3c</b>	4-FC <sub>6</sub> H <sub>4</sub>	<b>3i</b>	2-furyl
<b>3d</b>	3-OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	<b>3j</b>	2-thiophenyl
<b>3e</b>	2-OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	<b>3k</b>	2-naphthyl
<b>3f</b>	4-ClC <sub>6</sub> H <sub>4</sub>	<b>3l</b>	CH=CHC <sub>6</sub> H <sub>5</sub>

The *in vitro* cytotoxic activity of the compounds **3a-l** was evaluated against Hep-2 cell line which is derived from laryngeal carcinoma cells by MTT assay. The percentage of the cell viability was determined and cytotoxicity percentage was calculated (**Table 2**). The graphical representation was displayed in **Fig. 1**. On critically analyzing the results, all the compounds exhibit moderate to potent activities. From the cytotoxicity data it was noticed that the conjugates **3d** and **3e** with methoxy substitution (3-OCH<sub>3</sub> and 2-OCH<sub>3</sub>) have higher cytotoxicity of 56.7 and 45.5 % respectively. The results were in concord with the reported literature that the electron donating groups on aryl substituted chalcones exhibit relatively higher cytotoxicity than the electron withdrawing group<sup>17</sup>. The compounds **3a**, **3b**, **3f**, **3g** and **3l** with phenyl, 4-methyl, 4-chloro, 4-bromo and cinnamyl substitution displayed moderate activity with 25.5-29.1%. Moreover, the furyl (**3i**), thiophenyl (**3j**) and naphthyl (**3k**) substituted derivatives were found to possess less activity (12.6-15.8%) while the 4-fluoro and 3-nitro derivatives were found to possess very poor cytotoxic activity (5.6-8.4%). Based on the substitution on the phenyl ring, the cytotoxic activity decreases in the order of 2-OCH<sub>3</sub> > 3-OCH<sub>3</sub> > H > 4-Br > cinnamyl > 4-Cl > 4-CH<sub>3</sub> > 2-furyl > 2-thiophenyl > 2-naphthyl > 3-NO<sub>2</sub> > 4-F. From the results it seems that the methoxy group at both ortho and meta position have significant activity against the tested cell line. However, the modifications in the chalcone analogs can explore new cytotoxic agents.

**Table 2 Cytotoxicity (%) of the compounds 3a-3l**

Compound	3a	3b	3c	3d	3e	3f	3g	3h	3i	3j	3k	3l
Cell viability (%)	70.9	74.5	94.4	54.4	43.3	74.2	72.6	91.6	84.2	85.3	87.4	79.2
Cytotoxicity (%)	29.1	25.5	5.6	45.5	56.7	25.8	27.4	8.4	15.8	14.7	12.6	20.8



**Fig 1. Cell viability of compounds 3a-l**

## CONCLUSION

In the present work, the efficiently synthesized derivatives were tested against Hep-2 cancer cell line. The 2-methoxy (**3e**) and 3-methoxy (**3d**) substituted compounds displayed

high potency than the other substituted analogues. In conclusion, these findings suggest that the (*E*)-1-(2',4'-difluorobiphenyl-4-yl)-3-aryprop-2-en-1-ones exhibit cytotoxic activity and might be developed as an anticancer agent.

## REFERENCES

1. A.S. Girgis, S.S. Panda, M.N. Aziz, P.J. Steel, C.D. Hall and A.R. Katritzky, Rational design, synthesis, 2D-QSAR study of antioncological alkaloids against hepatoma and cervical carcinoma, *RSC Adv.*, V. 5(36), p. 28554-28569 (2015).
2. Z. Nowakowska, A review of anti-infective and anti-inflammatory chalcones, *Eur. J. Med. Chem.*, V. 42, p. 125–137 (2007).
3. A. Boumendjel, J. Boccard, P.A. Carrupt, E. Nicolle, M. Blanc, A. Geze, L. Choisnard, D. Wouessidjewe, E.L. Matera and C. Dumontet, Antimitotic and Antiproliferative Activities of Chalcones: Forward Structure-Activity Relationship, *J. Med. Chem.*, V. 51, p. 2307-2310 (2008).
4. M.Cabrera, M. Simoens, G. Falchi, M.L. Lavaggi, O.E. Piro, E.E. Castellano, A. Vidal, A. Azqueta, A. Monge, L.A. Cerain, G. Sagrera, G. Seoane, H. Cerecetto and M. Gonzalez, Synthetic chalcones, flavanones, and flavones as antitumoral agents: Biological evaluation and structure-activity relationships, *Bioorg. Med. Chem.*, V. 15, p. 3356-3367 (2007).
5. O. Sabzevari, G. Galati, M.Y. Moridani, A. Siraki, P.J. Brien, Molecular cytotoxic mechanisms of anticancer hydroxychalcones, *Chem. Biol. Interact.*, V. 148, p. 57-67 (2004).
6. Y.K. Rao, S.H. Fang and Y.M. Tzeng, (2004). Differential effects of synthesized 2'-oxygenated chalcone derivatives: modulation of human cell cycle phase distribution, *Bioorg. Med. Chem.*, V. 12, p. 2679-2686.
7. M. Liu, P. Wilairat, S.L. Croft, A.L.C. Tan and M.L. Go, Structure activity relationships of antileishmanial and antimalarial chalcones, *Bioorg. Med. Chem.*, V. 11, p. 2729-2738 (2003).
8. F. Lunardi, M. Guzela, A.T. Rodriguez, R. Correa, E.I. Mangrich, M. Steindel, E.C. Grisard, J. Assreuy, J.B. Calixto and A.R.S. Santos, Trypanocidal and leishmanicidal properties of substitution-containing chalcones, *Antimicrob. Agents Chemother.*, V. 47: p. 1449-1451 (2003).
9. X. Baj, F. Cerimele, M.U. Fukai, M. Waquas, P.M. Campbell, B. Govindarajan, C.J. Ber, T. Battle, D.A. Frank, K. Ye, E. Murad, W. Dubiel, G. Soff and J.L. Arbiser, Honokiol, a Small Molecular Weight Natural Product, Inhibits Angiogenesis *in Vitro* and Tumor Growth *in Vivo*, *J. Biol. Chem.*, V. 278, p. 35501-35507 (2003).
10. F. Chen, T. Wang, Y.F. Wu, Y. Gu, X.L. Xu, S. Zheng and X. Hu, Honokiol: Apotent chemotherapy candidate for human colorectal carcinoma, *World J. Gastroenterol.*, V. 10(23), p. 3459-3463 (2004).
11. L. Ma, J. Chen, X. Wang, X. Liang, Y. Luo, W. Zhu, T. Wang, M. Peng, S. Li, S. Jie, A. Peng, Y. Wei and L. Chen, Structural Modification of Honokiol, a Biphenyl Occurring in *Magnolia officinalis*: the Evaluation of Honokiol Analogues as Inhibitors of Angiogenesis and for Their Cytotoxicity and Structure–Activity Relationship, *J. Med. Chem.*, V. 54(19), p. 6469-6481 (2011).

12. Y. Kuo, L. Kuo and C. Chen, Four New C<sub>19</sub> Homolignans, Schiarisanrins A, B, and D and Cytotoxic Schiarisanrin C, from *Schizandra arisanensis*", *J. Org. Chem.*, V. 62(10), p. 3242-3245 (1997).
13. D. Chen, S. Zhang, L. Xie, J. Xie, K. Chen, Y. Kashiwada, B. Zhou, P. Wang, L.M. Cosentino and K. Lee, Anti-aids agents—XXVI. Structure-activity correlations of Gomisins-G-related anti-HIV lignans from *Kadsura interior* and of related synthetic analogues", *Bioorg. Med. Chem.*, V. 5(8), p. 1715-1723 (1997).
14. H.G.O. Alvim, E.L. Fagg, A.L. Oliveira, H.C.B. Oliveira, S.M. Freitas, M.E. Xavier, T.A. Soares, A.F. Gomes, F.C. Gozzo, W.A. Silva and B.A.D. Neto, Probing deep into the interaction of a fluorescent chalcone derivative and bovine serum albumin (BSA): an experimental and computational study, *Org. Biomol. Chem.*, V. 11, p. 4764-4777 (2013).
15. M. Fathimunnisa, H. Manikandan and S. Selvanayagam, Synthesis of novel (2E)-1-[4-(2',4'-difluorophenyl)phenyl]3-arylprop-2-en-1-ones: Investigation on spectral, antibacterial, molecular docking and theoretical studies", *J. Mol. Struct.*, V. 1099, p. 407-418 (2015).
16. S. Denizot and R. Lang, Rapid colorimetric assay for cell growth and survival, *J. Immunol. Methods.*, V. 89, p. 271-277 (1986).
17. Y. Zuo, Y. Yu, S. Wang, W. Shao, B. Zhou, L. Lin, Z. Luo, R. Huang, J. Du and X. Bu, Synthesis and cytotoxicity evaluation of biaryl-based chalcones and their potential in TNF $\alpha$ -induced nuclear factor- $\kappa$ B activation inhibition", *Eur. J. Med. Chem.*, V. 50, p. 393-404 (2012).